The Developmental Funds at this CCSG are also used to fund pilot projects in new research directions. The ability to provide funding for pilot projects is a highly effective mechanism for the Director and Program Leaders to influence the progress of cancer research at MIT and to rapidly respond to new opportunities and new strategic directions. It also represents a means to bring different Kl members together in collaborative projects. Pilot projects are expected to be novel and eariy-stage. They are often high risk/high reward in nature, and it is anticipated that the funding will allow for the generation of preliminary data that might form the basis of future grant applications. During the past grant period, eight pilot projects were selected for funding. Funds were awarded to projects in years 32, 34 and 37. Due to budget reductions in the CCSG, we were able to support fewer pilot projects than originally planned. However, as described below, projects that were funded have led to a series of very interesting observations, several publications and some new grant applications. In the current application, we are seeking funds sufficient to support 3 pilot projects annually. As is currentiy the case, applications will be reviewed by the Kl Director and a committee of faculty and awarded on the basis of both the quality of the application and on the novelty of the approaches proposed. Program leaders are encouraged to stimulate new directions of research within their Programs by encouraging their members to apply for pilot project funding; they also help to organize intra- and inter-programmatic collaborations. As has been true in the past, we anticipate that this mechanism will be very effective in assisting Kl members to embark on innovative research projects with potential for a significant impact on cancer diagnosis, treatment and control. With the introduction of the Koch Clinical Investigators Program as well as increased interactions with local clinical centers, there is an increased opportunity for clinically-oriented pilot projects.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts Institute of Technology
United States
Zip Code
McConnell, Russell E; Edward van Veen, J; Vidaki, Marina et al. (2016) A requirement for filopodia extension toward Slit during Robo-mediated axon repulsion. J Cell Biol 213:261-74
Puram, Rishi V; Kowalczyk, Monika S; de Boer, Carl G et al. (2016) Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell 165:303-16
Yin, Hao; Bogorad, Roman L; Barnes, Carmen et al. (2016) RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. J Hepatol 64:899-907
Hosios, Aaron M; Hecht, Vivian C; Danai, Laura V et al. (2016) Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. Dev Cell 36:540-9
Jhunjhunwala, Siddharth; Alvarez, David; Aresta-DaSilva, Stephanie et al. (2016) Frontline Science: Splenic progenitors aid in maintaining high neutrophil numbers at sites of sterile chronic inflammation. J Leukoc Biol 100:253-60
Tirosh, Itay; Izar, Benjamin; Prakadan, Sanjay M et al. (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189-96
Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167
Sun, Daphne; Dalin, Simona; Hemann, Michael T et al. (2016) Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci Rep 6:36198
Kimmerling, Robert J; Lee Szeto, Gregory; Li, Jennifer W et al. (2016) A microfluidic platform enabling single-cell RNA-seq of multigenerational lineages. Nat Commun 7:10220
Lowther, Daniel E; Goods, Brittany A; Lucca, Liliana E et al. (2016) PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 1:

Showing the most recent 10 out of 673 publications